Ritalin

Narcolepsy, Attention Deficit Hyperactivity Disorder

Treatment

20 Active Studies for Ritalin

What is Ritalin

Methylphenidate

The Generic name of this drug

Treatment Summary

Methylphenidate, also known as Ritalin, Concerta, and Biphentin, is a medication used to treat Attention-Deficit/Hyperactivity Disorder (ADHD). This drug works by increasing the levels of norepinephrine and dopamine in the brain, which helps improve concentration and reduce impulsivity. It is usually prescribed in combination with other treatments such as psychological, educational, and cognitive behavior therapies. Long-acting formulations of methylphenidate are the most effective and widely used treatment for ADHD, and can be given once daily for up to 12 hours. Methylphenidate carries a black box warning due to

Methylphenidate Hydrochloride

is the brand name

image of different drug pills on a surface

Ritalin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Methylphenidate Hydrochloride

Methylphenidate

1955

490

Effectiveness

How Ritalin Affects Patients

Methylphenidate is made up of two different forms (d- and l-isomers). The d-isomer is what actually works and binds to dopamine in the brain, particularly in the prefrontal cortex which is associated with Attention Deficit Hyperactivity Disorder (ADHD). In animal studies, this drug has been shown to increase movement and cause certain behaviors.

How Ritalin works in the body

Methylphenidate works to treat ADHD by increasing the amount of norepinephrine and dopamine in the brain. It does this by blocking certain receptors that keep these neurotransmitters from being released. Low doses of methylphenidate are used to improve focus, reduce impulsivity, and increase cognitive function, while higher doses can cause impaired cognition and locomotor-activating effects. Research shows that the drug works by interacting with the dopamine transporter gene (DAT1), the D4 receptor gene (DRD-4), and/or the D2 receptor gene, suggesting a possible mode of action.

When to interrupt dosage

The measure of Ritalin is contingent upon the recognized condition. The measure of dosage varies, in accordance with the technique of delivery indicated in the table beneath.

Condition

Dosage

Administration

Attention Deficit Hyperactivity Disorder

20.0 mg, , 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg, 27.0 mg, 36.0 mg, 54.0 mg, 50.0 mg, 5.0 mg, 2.5 mg, 5.0 mg/mL, 10.0 mg/mL, 18.0 mg, 80.0 mg, 15.0 mg, 10.0 mg/hour, 20.0 mg/hour, 15.0 mg/hour, 30.0 mg/hour, 30.0 mg/mL, 6.0 mg/mL, 7.5 mg/mL, 9.0 mg/mL, 8.6 mg, 25.9 mg, 17.3 mg, 1.0 mg/mL, 2.0 mg/mL, 25.0 mg, 35.0 mg, 55.0 mg, 70.0 mg, 85.0 mg, 100.0 mg, 45.0 mg, 72.0 mg, 63.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Capsule, Capsule - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, chewable - Oral, Solution, Solution - Oral, Tablet, chewable, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Suspension, extended release - Oral, Suspension, extended release, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral

Narcolepsy

20.0 mg, , 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg, 27.0 mg, 36.0 mg, 54.0 mg, 50.0 mg, 5.0 mg, 2.5 mg, 5.0 mg/mL, 10.0 mg/mL, 18.0 mg, 80.0 mg, 15.0 mg, 10.0 mg/hour, 20.0 mg/hour, 15.0 mg/hour, 30.0 mg/hour, 30.0 mg/mL, 6.0 mg/mL, 7.5 mg/mL, 9.0 mg/mL, 8.6 mg, 25.9 mg, 17.3 mg, 1.0 mg/mL, 2.0 mg/mL, 25.0 mg, 35.0 mg, 55.0 mg, 70.0 mg, 85.0 mg, 100.0 mg, 45.0 mg, 72.0 mg, 63.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Capsule, Capsule - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, chewable - Oral, Solution, Solution - Oral, Tablet, chewable, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Suspension, extended release - Oral, Suspension, extended release, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral

Warnings

Ritalin Contraindications

Condition

Risk Level

Notes

advanced arteriosclerosis

Do Not Combine

Gilles de la Tourette syndrome

Do Not Combine

Thyrotoxicosis

Do Not Combine

Pulse Frequency

Do Not Combine

Open-angle glaucoma

Do Not Combine

Hypertensive disease

Do Not Combine

Pulse Frequency

Do Not Combine

Tension-Type Headache

Do Not Combine

Generalized Anxiety Disorder

Do Not Combine

symptomatic cardiovascular disease

Do Not Combine

Tourette Syndrome

Do Not Combine

Pheochromocytoma

Do Not Combine

Tics

Do Not Combine

Agitation

Do Not Combine

There are 20 known major drug interactions with Ritalin.

Common Ritalin Drug Interactions

Drug Name

Risk Level

Description

Desflurane

Major

Methylphenidate may increase the hypertensive activities of Desflurane.

Diethyl ether

Major

Methylphenidate may increase the hypertensive activities of Diethyl ether.

Enflurane

Major

Methylphenidate may increase the hypertensive activities of Enflurane.

Halothane

Major

Methylphenidate may increase the hypertensive activities of Halothane.

Isoflurane

Major

Methylphenidate may increase the hypertensive activities of Isoflurane.

Ritalin Toxicity & Overdose Risk

Overdosing on caffeine can cause vomiting, restlessness, shaking, increased reflexes, muscle twitching, seizures, elation, confusion, seeing things that are not real, extreme excitement, sweating, blushing, headaches, high fever, rapid heartbeat, abnormal heart rhythm, high blood pressure, dilated pupils, and dryness of the mouth. The toxic dose in mice has been found to be 190mg/kg when taken orally.

image of a doctor in a lab doing drug, clinical research

Ritalin Novel Uses: Which Conditions Have a Clinical Trial Featuring Ritalin?

Currently, there are 84 studies assessing the potential of Ritalin in alleviating Attention Deficit Hyperactivity Disorder.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

61 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Narcolepsy

2 Actively Recruiting

Not Applicable, Phase 1

Ritalin Reviews: What are patients saying about Ritalin?

5

Patient Review

9/12/2022

Ritalin for Attention Deficit Disorder with Hyperactivity

I'm 32 years old and have always had a very strong case of ADHD. I took Ritalin for the first time today and feel better than ever before. There are lots of things that feel better now while taking Ritalin. I wouldn't go back to not having it because it's made my life much more focused and comfortable.

5

Patient Review

9/2/2021

Ritalin for Attention Deficit Disorder with Hyperactivity

Ritalyn has helped me so much with my ADHD. I'm able to focus better and function more smoothly in all aspects of life.

3.7

Patient Review

6/6/2016

Ritalin for Attention Deficit Disorder with Hyperactivity

I took this medication for my ADHD and it did help me focus more; however, the depression that set in after it wore off was really tough to deal with. Additionally, I had headaches almost every day while taking it which led to me discontinuing use.

3.7

Patient Review

10/20/2020

Ritalin for Attention Deficit Disorder with Hyperactivity

I've found this treatment to be mostly effective. I'm more productive when on it and generally feel happier. Though, I do experience some physical side effects that are a bit strange. Also,I'm a bit nervous because many people say this causes depression--which is not good considering my history of self-harm and suicide attempts.

3.7

Patient Review

3/22/2017

Ritalin for Attention Deficit Disorder with Hyperactivity

This medication worked really well for me and was much better than other options I've tried.

2.7

Patient Review

10/15/2022

Ritalin for Attention Deficit Disorder with Hyperactivity

I've been on this medication for about a year as a 15-year-old trans male. I switched to Ritalin a few weeks ago and saw no change other than an inability to focus and worse tics. I moved up the dosage to 40mg a few days ago and have only experienced worsening symptoms like depression, anxiety, emotional instability, constant hunger, weight gain, and breakdowns. My parents don't believe me so I'm stuck until my next appointment.

2

Patient Review

9/18/2016

Ritalin for Attention Deficit Disorder with Hyperactivity

I took Ritalin for four years to help with my ADHD. However, I always felt sick after taking it and had a hard time sleeping. Now I'm dealing with depression.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ritalin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Ritalin or Adderall better?

"Ritalin works more quickly than Adderall does, but Adderall lasts longer. Adderall is active for four to six hours, while Ritalin only lasts for two to three hours."

Answered by AI

How does taking Ritalin make you feel?

"ADHD patients on Ritalin typically say they feel more focus, in control, and have a greater sense of clarity. Ritalin, as a stimulant, can make people feel more alert, awake, and talkative, or even create a sense of euphoria."

Answered by AI

What does Ritalin do to a person?

"What is the purpose of Ritalin?

Ritalin is a medication that stimulates the mind and body in adults and can calm children down. It is most commonly used to treat attention deficit hyperactivity disorder (ADHD) in children. However, it is not usually recommended for children younger than 6 years old."

Answered by AI

Is Ritalin different from Adderall?

"Both Ritalin and Adderall work similarly in the brain and have similar side effects. The primary difference is that Ritalin works more quickly and reaches peak performance earlier than Adderall, which stays in the system for a longer period of time."

Answered by AI

Clinical Trials for Ritalin

Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Ritalin clinical trials?

We made a collection of clinical trials featuring Ritalin, we think they might fit your search criteria.
Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Recruiting
Device

UCSF Nancy Friend Pritzker Psychiatry Building

Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

Waitlist Available
Online Trial

The University of Texas at Austin

Have you considered Ritalin clinical trials?

We made a collection of clinical trials featuring Ritalin, we think they might fit your search criteria.
Go to Trials
Image of Louisiana State University in Baton Rouge, United States.

Virtual Reality for ADHD

18 - 25
All Sexes
Baton Rouge, LA

The goal of this larger parallel group randomized trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.

Phase 4
Waitlist Available

Louisiana State University (+1 Sites)

Joshua M Langberg, PhD

Image of Duke University in Durham, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Durham, NC

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Duke University

John Mitchell, PhD

Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment

Phase 1 & 2
Waitlist Available

Kennedy Krieger Institute

Alison E Pritchard, PhD

Image of Montana State University in Bozeman, United States.

Speech-Gesture Combinations for Autism

Any Age
All Sexes
Bozeman, MT

This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and/or minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \[cry\], can promote successful understanding of words like "cry". The overarching goal is to help families effectively utilize gestures to support communication with their children.

Recruiting
Has No Placebo

Montana State University

Have you considered Ritalin clinical trials?

We made a collection of clinical trials featuring Ritalin, we think they might fit your search criteria.
Go to Trials